Why IsoRay (ISR) Stock Is Surging Today - TheStreet

NEW YORK (TheStreet) -- Shares of IsoRay  (ISR) - Get Report soared 31.16% to $1.81 in morning trading Tuesday after the medical technology company announced positive results of its Cesium-131 seed in a young female patient with an inoperable glioblastoma brain tumor.

The seven-year-old Peruvian girl was diagnosed with a potentially life-threatening brain cancer called a glioblastoma multiforme (GBM). The 2.7 cm tumor was found close to her brain stem, which made it inoperable.

Doctors delivered the Cesium-131 seed directly into the brain tumor through a stereotactic implant in July. In September, more than 99% of the radiation from the implant had been delivered 10 weeks after the procedure. An MRI scan revealed a 70% reduction in the tumor's mass.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

IsoRay also announced the patient had significant difficulty walking after her diagnosis, but she began to walk without assistance a few weeks after doctors delivered the implant. The girl has returned to school without assistance or special needs and resumed normal activities.

More than 6.5 million shares had changed hands as of 11:02 a.m., compared to the average volume of 969,805.

Image placeholder title

ISR

data by

YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.